These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy. de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091 [TBL] [Abstract][Full Text] [Related]
73. Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients. Hellinger J; Cohen C; Morris A; Sheble-Hall S; Gordon D; Foy C; Jackson-Pope L; Shevitz A; van Schaic E HIV Clin Trials; 2005; 6(2):107-17. PubMed ID: 15983895 [TBL] [Abstract][Full Text] [Related]
74. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients. Ortega KL; Vale DA; Magalhães MH J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845 [TBL] [Abstract][Full Text] [Related]
75. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients. Kozal MJ; Hullsiek KH; Leduc R; Novak RM; MacArthur RD; Lawrence J; Baxter JD; Antivir Ther; 2006; 11(4):457-63. PubMed ID: 16856619 [TBL] [Abstract][Full Text] [Related]
76. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820 [TBL] [Abstract][Full Text] [Related]
77. HIV-1 protease inhibitors. A review for clinicians. Deeks SG; Smith M; Holodniy M; Kahn JO JAMA; 1997 Jan; 277(2):145-53. PubMed ID: 8990341 [TBL] [Abstract][Full Text] [Related]
79. The relationship between race and HIV-distal sensory polyneuropathy in a large cohort of US women. Anziska Y; Helzner EP; Crystal H; Glesby MJ; Plankey M; Weber K; Golub E; Burian P J Neurol Sci; 2012 Apr; 315(1-2):129-32. PubMed ID: 22123155 [TBL] [Abstract][Full Text] [Related]
80. Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age. Möller J; Desai K; Simpson K; Baran RW; Van de Steen O; Dietz B; Gooch K J Med Econ; 2014 Apr; 17(4):250-8. PubMed ID: 24351091 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]